Celcuity
Manufacturing · Minnesota, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
16305 36th Ave N Ste 100, Minneapolis, M...Phone Number
(763) 392-0767Website
www.celcuity.comRevenue
-Stock Symbol
CELCIndustry
About Celcuity
Celcuity is a commercial-stage oncology company that specializes in cancer therapies, particularly through its approved kinase inhibitor, REVTORPYK™ (gedatolisib). This treatment targets the PI3K/AKT/mTOR (PAM) pathway, which is crucial in the progression of various cancers. The company aims to improve patient outcomes by evaluating gedatolisib across a range of solid tumors, with ongoing clinical trials for breast and prostate cancer. Celcuity's primary clients include healthcare providers and patients seeking advanced cancer treatment options.Explore more
Celcuity Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Celcuity
Compare insights from companies similar to Celcuity, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Celcuity Tech Stack
A closer look at the technologies used by Celcuity
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Celcuity
Sign Up For FreeTo access detailed company insights
Celcuity is a commercial-stage oncology company that specializes in cancer therapies, particularly through its approved kinase inhibitor, REVTORPYK™ (gedatolisib). This treatment targets the PI3K/AKT/mTOR (PAM) pathway, which is crucial in the progression of various cancers. The company aims to improve patient outcomes by evaluating gedatolisib acr... Read More
